Abstract. Vanishing white matter disease (VWM) is a progressive cavitating disease of central white matter due to a deficiency of the translation initiation factor eIF2B. Oligodendrocytes appear to be numerically increased in some white matter areas, while decreased in others. We compared oligodendrocytes of cerebral, cerebellar, and pontine white matter from 5 VWM patients with those of age-matched controls by light microscopy and immunohistochemistry using antibodies to activated caspase-3, bak, bax, bcl-2, survivin, and Ki-67, as well as by the TUNEL technique. Oligodendrocytes were identified morphologically and quantified using an ocular grid. We observed statistically significant increases in their densities at all sites; Ki-67-labeled oligodendrocytes were identified in 2 of 5 patients. Apoptotic oligodendrocytes were documented in 3 of 5 patients, while bcl-2 and survivin labeling was observed in 2 of 5 and 2 of 2 patients, respectively. There was a trend toward an increase in apoptotic labeling of oligodendrocytes that was strongest in the cerebrum, the major locus of VWM, in the youngest and most severely affected patients. These data conclusively demonstrate increased oligodendrocytic densities in VWM; the increase is not an artifact of white matter contraction. Our data also document that oligodendrocytes undergo apoptosis, perhaps in conjunction with major neurologic crises, and that a subset of oligodendrocytes are able to persist and proliferate. Conflicting proliferative, cell-death, and survival signals impact the oligodendrocytes of VWM.
INTRODUCTION
Vanishing white matter disease (VWM) (1) , also known as childhood ataxia with diffuse central nervous system hypomyelination (CACH) (2) , is a recently identified disorder of central white matter. It is associated with a defect in any of the 5 genes that encode the subunits of eIF2B, a protein complex that is involved in the regulation of translation initiation in every human cell. The disorder is usually characterized clinically by a normal to mildly delayed developmental history, followed by an episodic but progressive neurological decline usually beginning early in childhood, although onset is possible anytime between the neonatal period and adulthood. Neurological findings consist mainly of cerebellar ataxia and spasticity, but may also include optic atrophy and epilepsy. Intellectual functioning is relatively preserved. Episodes of deterioration may follow infection with fever or minor head trauma, leading to a rapid loss of motor function, lethargy, and sometimes coma.
The diagnosis is primarily based on magnetic resonance imaging (MRI) findings, which reveal a diffuse signal abnormality of the cerebral white matter usually sparing other white matter tracts (e.g. corpus callosum, internal capsule, anterior commissure) (1, 3) . The hallmark of the disease on MRI is white matter rarefaction and cystic degeneration on proton density and FLAIR images. Genetic testing for a defect in any 1 of the 5 eIF2B subunit genes is the gold standard in diagnosis (4) (5) (6) .
At autopsy VWM patients reveal cystic cavitations of deep cerebral, with relative preservation of subcortical, white matter. Histologically, the disease exhibits an early, milder lesion of white matter pallor and vacuolation with relatively mild astrogliosis (1-3, 7, 8) . Ultimately, there is diffuse loss of both myelin and axons, though it is still a matter of debate as to which occurs first and whether the losses are equivalent (1) (2) (3) (7) (8) (9) (10) . The gray matter is typically normal in appearance (1) (2) (3) . Recently, morphologic evidence has been presented that suggests a role for apoptosis among pontine, but not cerebral, oligodendrocytes of ''myelinopathia centralis diffusa'' (VWM) patients (9) ; moreover, some of the analyses were conducted on active pontine lesions of uncertain nature and unspecified location.
Complicating the histologic picture of this disease, however, is the observation of focal regions of relatively preserved white matter, confirmatory of the MRI findings (e.g. subcortical white matter and anterior commissure). Areas of white matter preservation may be adjacent to areas of cavitation and often exhibit an apparent increased density of oligodendrocytes (3, 10) . Some authors have cautioned that, given the extent of tissue loss in nearby regions, this increase in oligodendroglial density may be an artifact of white matter contraction (7) . The significance and etiology of this observation, however, has remained unresolved. If this does represent a true overproduction of new oligodendrocytes, available data would indicate that their most likely source would be a glial precursor cell because mature oligodendrocytes are essentially post-mitotic cells and unlikely to divide (11) . Our study was designed to investigate the paradox of increased oligodendrocytic density in a disease of diffusely cavitated white matter that reflects profound losses of oligodendrocytes, myelin sheaths, and axons. We also asked if apoptosis represents a major mechanism of oligodendrocytic demise in VWM disease and, if so, why are there areas of both increased and decreased oligodendroglial density? The answer to both questions may eventually offer unique insights into the disease mechanism, particularly as it relates to the critically important eIF2B, whose deficiency underlies this disorder. A portion of this work has been published previously in abstract form (12) .
MATERIALS AND METHODS
Brain tissue from 5 VWM patients and 6 controls was collected for analysis via autopsy at both the University of Rochester Medical Center in Rochester, New York and the Free University Medical Center in Amsterdam, the Netherlands. At the time of autopsy, all of the patients' next of kin consented to the use of patient tissues for research. The 5 patients identified as having VWM were confirmed by genetic testing (4, 13) . Controls were selected with an attempt to age-match patients (Ͻ18 years old) and without significant or confounding neuropathologic findings at the time of autopsy. The ages for the VWM patients ranged from 3 months to 16 years, while the controls ranged from 3 months to 18 years of age. Table 1 outlines the clinical and demographic information of the 11 patients. The postmortem intervals (PMI) for the VWM patients ranged from 1 to 6 hours with a mean of 3.6 Ϯ 1.8 hours, while the controls had intervals ranging from 8 to 24 hours with a mean of 15.1 Ϯ 7.5 hours ( Table 1 ). The brains were fixed for a minimum of 7 days in Formalin before they were sectioned. Selected portions of each brain were embedded in paraffin. Our study focused on the oligodendrocytes from 2 prominent regions of white matter involvement in VWM: the cerebrum and cerebellum; the central tegmental tract of the pons, which shows consistent involvement, and the anterior commissure, which is characteristically preserved in VWM, were also studied. The cerebral white matter specimens evaluated were selected from relatively preserved subcortical areas adjacent to cavitary foci (Fig. 1A, B ) rather than areas of decreased oligodendrocytic density (Fig. 1C) . The corresponding subcortical areas from the controls were compared to those of the VWM patients. Cerebellar and pontine sections for Controls 3, 4, 5 and 6 were unavailable. Similarly, we initially obtained anterior commissures from only 2 sources: Patient 2 and Control 4, matched for both age and sex; we later added Control 1 for comparative carbonic anhydrase II (CAII) and survivin immunostaining. A screening survivin immunostain of Patient 2 was so surprisingly positive that it was repeated with an additional patient (#5) and more controls. Survivin immunostaining and quantification were restricted to cerebral white matter samples of Patients 2 and 5, Control 1, and 3 additional ''normal'' controls (ages: 9, 13 and 22 years; PMI: 21, 24, and 28 hours, respectively). Tissue sections were cut from the paraffin blocks at a thickness of 7 m and stained routinely with hematoxylin and eosin (H&E), Luxol fast blue-periodic acid-Schiff (LFB-PAS, myelin) and Bodian (axons) techniques.
Immunohistochemical Staining
All slides were deparaffinized in xylene, dehydrated in absolute and 95% ethanol to distilled (D)H 2 O. They were then placed for 10 min in 3% hydrogen peroxide (H 2 O 2 ) to quench 620 VAN endogenous peroxidase, rinsed in DH 2 O, and placed in phosphate buffered saline (PBS). A 5% normal serum of the secondary host species was used to block endogenous biotin. The slides were incubated with primary antibody overnight in a 6ЊC refrigerator. On day 2, the specimens were warmed to room temperature for 1 hour and rinsed in PBS before the secondary biotinylated antibody was applied and incubated for 30 min at room temperature. The slides were then rinsed with PBS and incubated with 1:1,000 streptavidin horseradish peroxidase (Jackson Lab, West Grove, PA) for 30 min. The slides were rinsed in PBS, incubated in the chromagen aminoethyl carbazol (AEC) (ScyTek Laboratory, Logan, UT, used according to the vendor's protocol) for 5 min, rinsed with PBS, and placed in DH 2 O. They were then counterstained in non-alcoholic LillieMayer hematoxylin for 30 seconds and covered with aqueous mounting media. In selected staining protocols (Table 2 ), antibody retrieval was performed using a Biocare Medical 10X Antigen Decloaker (Biocare, Walnut Creek, CA) in a 1:9 dilution after H 2 O 2 and before blocking. In such cases, the slides were placed in an automated Biocare Medical decloaking chamber for 20 min at 125ЊC and 24 psi, after which the device was cooled to 90ЊC for an additional 20 min and the specimens were removed. They were rinsed in DH 2 O, PBS, and cooled to room temperature before primary antibodies were applied. Double immunostaining included the addition of another chromagen, Vector SG substrate kit for peroxidase (Vector Laboratories, Burlingame, CA) used according to the vendor's protocol. The Vector SG (blue-gray) chromagen was always applied with the first antibody, while the AEC (red-brown) chromagen was linked to the second antibody. When double immunostaining 
Quantification
TUNEL, Activated Caspase-3, Bax, Bak: All slides were examined with an Olympus BH-2 microscope using a ϫ40 objective with a ϫ10 eyepiece. A 10 ϫ 10 oculometric grid (Miller disk) was used to specify a precise area for quantification. For each tissue section stained for activated caspase-3, bax, bak, or TUNEL, the total number of oligodendrocytes (both labeled and unlabeled) was counted individually in 3 randomly selected regions of preserved white matter within similar tissue regions. At this magnification, each grid approximated an area equal to 1 ϫ 10 Ϫ4 cm 2 . For each of these stains, labeled oligodendrocytes were counted individually and expressed as a fraction of the total number of oligodendrocytic nuclei stained with hematoxylin and the antibody, when appropriate. The results from the requisite 3 counts were expressed as a percentage and averaged.
Oligodendrocytic densities were derived using data from counts performed by staining for caspase-3, bak, and bax. As mentioned previously, the total number of oligodendrocytes present in each of 3 grid regions (where each grid approximated 1.0 ϫ 10 Ϫ4 cm 2 ) was counted for each stain of each subject's 3 brain regions. This yielded a total of 9 separate grid counts (3 grid counts ϫ 3 stains) for each subject's brain region (except in the case of the anterior commissure, for which only activated caspase-3 was analyzed). The geometric means for each stain (by patient/control status) are shown in Figure 2 , along with their associated 90% confidence limits, based on log transforming and then averaging the 9 repeated measures for each subject. Variances on the transformed scale were pooled over cases and controls. The same method was applied for the oligodendrocytic labeling (percent) but using the square-root transform rather than the logarithmic one.
Ki-67, Bcl-2 and Survivin: Because of the relative scarcity of positively labeled oligodendrocytes in Ki-67-and bcl-2-stained tissue sections, a separate quantification method was used. For these stains, 10 adjacent areas of white matter were examined using a ϫ20 objective with otherwise identical equipment. The final units of measurement were given as total number of labeled oligodendrocytes per 10 fields, which, at this magnification, totaled 4 ϫ 10 Ϫ3 cm 2 . The relatively high prevalence of survivin-immunoreactive oligodendrocytes permitted quantification as done for TUNEL, and so forth.
Criteria for Oligodendrocytic Positivity
Cells counted as ''positive'' were those that 1) were morphologically consistent with oligodendrocytes (i.e. dense round nuclei, often with a small nucleolus; minimal cytoplasm or perinuclear halo), and 2) possessed a degree of nuclear, cytoplasmic (usually a perinuclear rim) or both nuclear and cytoplasmic staining above that of background staining. Serial sections of selected cases were immunostained for common leukocyte antigen and CAII to ensure that lymphocytes were not being counted. Double immunostaining with antibodies to CAII and activated caspase-3 was performed in the cerebrum of Patient 5 in order to confirm oligodendrocytic identification and labeling. Similarly, antibodies to CAII/bcl-2 and CAII/Ki-67 were used to double immunostain the anterior commissure of Patient 2 and the cerebral white matter of Patients 2 and 5. Finally, we double immunostained the cerebral section of patient 2 with antibodies to proteolipid protein (PLP)/Ki-67 and to PLP/bcl-2. CAII is an established marker for oligodendrocytes, including some that are mature, usually the smaller type I/II that myelinate small diameter fibers in rodents (14) . CAII labels approximately 20% to 30% in human cerebral white matter according to previous investigators, who also report a fine granular staining of myelin with this antibody (15) . The immunoreactivity of myelin varies in intensity between tracts (personal observation). In our well-fixed, paraffin embedded neonatal positive immunostaining control, approximately 80% to 90% of white matter cells morphologically consistent with oligodendrocytes are labeled with the CAII antibody, but the intensity of immunoreactivity varies considerably. Some have reported that all oligodendrocytes in VWM and controls could be labeled with a CAII antibody (10) .
Statistical Methods
In order to symmetrize the error distributions and make the homoscedasticity assumption more tenable, cell density counts were log transformed and cell death marker rates were square root transformed. Each outcome was analyzed separately using repeated measures ANOVA. For the cell death marker model, separate linear mixed effects models were fit to the data for each brain section, each including fixed effects for treatment, stain, and their interactions, plus a random effect for subject to account for the correlation between measurements from each subject. For the cell density model, a single linear mixed effects model was fit to the entire data set with fixed effects for section, treatment, and their interaction, plus a random effect for subject. We further allowed for separate covariance matrix estimates by treatment. In all cases, restricted maximum likelihood (REML) was used and inference for the fixed effects was based on the robust ''sandwich'' estimator of variance. If any interactions were not significant, they were removed from the models. Bcl-2, Ki-67 and survivin results were not analyzed due to the small amount of data.
RESULTS

Cell Density
There was a 2.27-fold increase in oligodendrocytic density, based on counts of the total number of oligodendrocytic nuclei, between patients and controls (p Ͼ 0.0001; 95% CI ϭ 1.88, 2.74) in the cerebrum, cerebellum, and pons collectively (Fig. 2) . There also appeared to be an increase in oligodendrocytic density with age. The slope was 110 Ϯ 4.2 (SE), p ϭ 0.08, with 38.6% of the total variance explained by the regression line, 35 .3% attributable to within-subject variation, and 26.1% due to the residual variance of the subject-specific means about the regression line (Fig. 3) . Despite this high density of cells, there was a paucity of myelin, particularly in the cerebral hemispheres as observed on Luxol fast blue staining (Fig. 4A) , while the axons were largely spared (Fig. 4B) . The anterior commissure of the selected VWM patient (Patient 2) had a markedly increased cell density (Fig. 5A ) compared to the age-and sex-matched control (Fig. 5B) , which was of approximately equal size (0.25 and 0.28 cm, respectively); it displayed minimal evidence of myelin pallor and a rare macrophage (Fig. 5C ). The number of CAII-immunoreactive oligodendrocytes in the anterior commissure of Patient 2 was markedly reduced (Fig. 5D ) in comparison to his affected centrum semiovale (Fig. 5E ) and the adjacent unaffected anterior limb of the internal capsule, where approximately 40% to 60% and 80% to 90% of oligodendrocytes were immunoreactive, respectively. The anterior commissure of Patient 2 also lacked the CAII immunoreactivity of myelin seen in controls (Fig. 5D ).
Bcl-2
Bcl-2 expression was detected in few oligodendrocytes of the cerebrum and anterior commissure of Patient 2 (9 cells/10 medium-power fields [mpf]), the cerebellum (4 cells/10 mpf) of Patient 3, and the cerebellum (14 cells/ 10 mpf) and pons (10 cells/10 mpf) of Patient 4. Additional expression could be identified by enhancing the antigen retrieval (Fig. 6A, B) . Labeling was absent in controls. Double immunostaining for CAII and bcl-2 in Patient 2 confirmed that oligodendrocytes expressed bcl-2 (Fig. 6C) ; some of these had abundant cytoplasm, as noted previously (10) .
Survivin
Survivin expression (Fig. 7A) immunostaining for CAII (pink to red) and bcl-2 (gray to pale blue) (arrows). Note the variability in nuclear immunoreactivity for CAII and the gray-blue cytoplasmic immunoreaction product representing the presence of both CAII and bcl-2. A lymphocyte (L) near a blood vessel (BV) with its constitutive expression of bcl-2 displays a dark blue immunoreactivity (C). Inset: A higher magnification of another field demonstrates the pale pink nuclear staining for CAII in the oligodendrocytes, one of which has gray to pale blue cytoplasmic staining for combined bcl-2 and CAII. A, B: bcl-2 (AEC), original magnification, ϫ225; C: CAII (MACH 3)/bcl-2 (SG), original magnification, ϫ150; Inset, ϫ450. confirmed that oligodendrocytes expressed survivin (Fig.  7B) . It is noteworthy that, despite many survivin-immunoreactive oligodendrocytes being seen in the cerebral white matter of Patient 2, the anterior commissure consistently exhibited only a few.
Ki-67
Ki-67 expression was detected infrequently in oligodendrocytes in the cerebrum (4 cells/10 mpf), cerebellum (7 cells/10 mpf) and anterior commissure (1 cell/10 mpf) of Patient 2 (Fig. 8) , in the cerebrum (1 cell/10 mpf) of Patient 5, and in the cerebellum (4 cells/10 mpf) of Patient 5. Perivascular cells, presumably microglia, were also infrequently immunoreactive. The commonest immunoreactive nucleus was large and irregular with prominent clumps of chromatin; its cell of origin could not be determined, but they were unstained with the antibody to CAII. Of note, no small microglia-like cells consistent with glial precursors were labeled (14) . Labeling was absent in controls. Double immunostaining for CAII and Ki-67 in Patient 2 confirmed that oligodendrocytes expressed Ki-67 (Fig. 8, inset) .
TUNEL
A high number of oligodendrocytes (30% to 70%) labeled for TUNEL in both patients and controls (Figs. 9,  10 ). There was a correlation between TUNEL and other pro-apoptotic stains in the cerebrum (Fig. 9 ), but no correlation was identifiable in other brain regions (data not shown).
Activated Caspase-3
On average, activated caspase-3 expression was mildly increased among oligodendrocytes in all 3 brain regions of patients versus controls. On the square root scale, these estimated mean increases were 0.079 (Ϫ0.118, 0.276) for cerebrum (p ϭ 0.427), 0.157 (0.038, 0.276) for cerebellum (p ϭ 0.011), and 0.183 (0.037, 0.329) for pons (p ϭ 0.015). However, it was most notably increased in the cerebrum of Patient 5 (20.4%), less so in the cerebra of Patients 1 and 4 (7.1% and 5.8%, respectively), and virtually undetectable in the cerebra of Patients 2 and 3 (0.2% and 0.0%, respectively). In view of the youth of Patient 5, when oligodendrocytes are normally programmed to die by apoptosis (22) (23) (24) (25) (26) , a more anterior frontal lobe section was immunostained with 2 agematched ''normal'' controls (Controls 5 and 6). This evaluation revealed a lower number of immunoreactive oligodendrocytes (13.7%) in Patient 5, but none in Control 5 and only 3.6% in Control 6. In this patient, numerous oligodendrocytes and others (Fig. 11A-C) were apoptotic. Varying stages of nuclear degeneration were detected in oligodendrocytes and probable oligodendrocytes with CAII-and activated caspase-3 immunostains, including ''foamy'' (7) oligodendrocytes (Fig. 11D-H) . Double immunostaining for CAII and activated caspase-3 in Patient 5 confirmed that classical and ''foamy'' oligodendrocytes (Fig. 12A, B) and oligodendrocytes with unusually abundant cytoplasm (10) (Fig. 12C) often expressed activated caspase-3. Of note, only classical oligodendrocytes were included in the quantitative analysis. Activated caspase-3 was either absent or was present at low to moderate levels in the 6 controls.
Bax
Bax expression showed a statistically insignificant increase in the labeling of oligodendrocytes of the cerebral sections of VWM patients compared to controls (data not shown), but expression was variable in the cerebellar and pontine sections of both patients and controls. In particular, bax staining was markedly elevated in the cerebellum of Patient 2 and in the pons of Control 1.
Bak
Bak staining was mildly elevated over controls in oligodendrocytes of the cerebral sections of VWM patients (data not shown). In Control 1, however, bak was markedly elevated in both cerebellar and pontine sections.
DISCUSSION
Our study has demonstrated a statistically significant increased density of oligodendrocytes, that oligodendrocytes are being subjected to abnormal apoptotic and mitogenic signals, and that oligodendrocytes are dying by apoptosis in VWM.
Oligodendrocytosis in VWM Is Not Due to Tissue Contraction
We (3) and others (10) have previously reported increased numbers of oligodendrocytes in VWM, the latter providing a mean increase figure of 200% to 300%. In our current study we have confirmed this increase in areas of preserved white matter when compared to similar regions in controls (2.27-fold overall) and found that this increase was statistically significant. Moreover, the presence of a highly increased cell density in the anterior commissure (patient to control ratio of 9.9:1), an area unaffected by white matter cavitation, provides convincing evidence that this increase in oligodendrocytic density is absolute and is not an artifact of white matter contraction, as had been entertained previously (7) . The precise cause of this increase in oligodendrocytic density is unclear at present; it could be the result of either a decrease in normal programmed cell death (10, see below) or a proliferative response, or both. If it reflects a proliferative response, current wisdom would opine that the most likely source for new oligodendrocytes at this age is a glial precursor cell or immature oligodendrocytes. However, while most consider mature oligodendrocytes to be post-mitotic cells and incapable of mitotic division, there is good evidence that mature oligodendrocytes can rarely incorporate tritiated thymidine (reviewed A, B, C) , ''foamy'' oligodendrocytes (A, double arrows), and oligodendrocytes with unusually abundant cytoplasm (B and particularly C). Original magnifications: A, ϫ225; B, ϫ450; C, ϫ550. in 11) and proliferate under non-neoplastic pathologic conditions (15) .
Oligodendrocytes in VWM Display Proliferative and Anti-Apoptotic Markers
In contrast to the study cited earlier (10), we were able to identify Ki-67-immunoreactive oligodendrocytes in VWM patients. Ki-67 is a highly predictive and wellknown marker for proliferative potential. We also found that some oligodendrocytes were immunoreactive for bcl-2. Bcl-2, when expressed at sufficient levels, imparts a defense against certain mechanisms of apoptosis, particularly those instigated by pro-apoptotic members of the bcl-2 family such as bak and bax (16) (17) (18) (19) . We had much greater success in detecting another anti-apoptotic protein in VWM oligodendrocytes of the cavitated centrum semiovale, survivin. Survivin is a member of the inhibitor of apoptosis protein (IAP) family, which interferes with caspases (reviewed in 20). It is important to note that the number of Ki-67-positive oligodendrocytes identified in the abnormal white matter of VWM is small, but this same paucity typifies low-grade oligodendroglial neoplasms and no positive oligodendrocytes were seen in our controls. Moreover, because our immunohistochemical assays were done in batches, consisting of all VWM patients and controls, to ensure uniformity of processing between groups, the numbers for Ki-67 and bcl-2 are low estimates. We also modified the antigen retrieval process, such as by using high pH, on selected patients and controls and observed a higher number of immunoreactive oligodendrocytes in VWM (Fig. 6) ; these deviations from the group control conditions were not included in our quantitative data. If one considers the anterior commissure as an earlier or milder lesion than that in the cavitated centrum semiovale, then the comparatively greater number of bcl-2-immunoreactive oligodendrocytes would suggest that abnormal anti-apoptotic responses are more dominant than oligodendroglial proliferation; survivin, however, does not appear to be operative in this location. An assessment of the presence and mitogenic potential of oligodendroglial precursors has not been included in our current study, because the reagents currently available to demonstrate these cells (e.g. antibodies to NG2 or PDGF-␣ receptor) are considered of dubious value in routinely fixed and processed samples such as we used; so the possible role of oligodendroglial precursors in this phenomenon remains unknown. Despite the marked increase in the number of oligodendrocytes in the anterior commissure, there was a decrease in stainable myelin (best appreciated by using Luxol fast blue staining and CAII immunoreactivity), without a significant macrophage response (Fig. 5) . It is unclear if this myelin deficit reflects a true hypomyelination (2, 7) and whether it is directly related to increased cell density, to oligodendrocytic immaturity (10) , to some intrinsic oligodendrocytic dysfunction (7, 10) , or to persistent proliferative cues directed at oligodendrocytes (reviewed in 21).
Our small sample of VWM patients also demonstrated an apparent increase in oligodendrocytic density with age (Fig. 3) . This is in contrast to normal white matter in which oligodendrocytic density peaks early in development and declines sharply (perhaps by as much as 50%) as oligodendrocytes compete for axonal contact and trophic factors, before finally achieving a sustainable population (21) (22) (23) (24) (25) (26) . In VWM patients, increasing age may allow prolonged exposure to abnormal mitogenic influences. Alternatively, younger patients may have a more aggressive disease resulting in greater oligodendrocytic death.
Oligodendrocytes in VWM Suffer an Apoptotic Death
It is also possible that the presence of proliferative signals induces cell death in some VWM oligodendrocytes. Apoptosis in oligodendroglia can result from a mixture of proliferative and cell-arrest signals (22, (27) (28) (29) . If these labeled cells are reacting to conflicting signals, they may represent a subpopulation of oligodendrocytes destined to die. Alternatively, an overexpression of anti-apoptotic proteins, such as bcl-2, might reverse their normal anti-apoptotic function to one of pro-apoptosis (30) .
Apoptosis results from a highly complex, intracellular cascade of events that ultimately leads to cell death. Apoptosis has been implicated, but often not proven, in an increasing number of neurological diseases (31) . Numerous immunohistochemical markers for pro-and anti-apoptotic proteins are currently available for the study of apoptosis (32) . Bax and bak are both pro-apoptotic members of the bcl-2 family of proteins, which increase the permeability of the mitochondrial membrane. Caspases are another well-studied family of pro-apoptotic proteins. Caspase-3 is among a small family of caspases known as effector or execution caspases that, once activated, degrade a variety of cellular proteins, irreversibly committing the cell to an apoptotic death (reviewed in 32). Activated caspase-3 is considered among the most sensitive and specific markers for apoptosis (33) . TUNEL, one of the original techniques employed in labeling apoptotic cells, is now known to label both apoptotic and necrotic cells (reviewed in 32). However, its use in conjunction with activated caspase-3 immunohistochemistry is a highly reliable morphologic assay for apoptosis (reviewed in 34).
There was a mild trend toward an increase in apoptotic labeling of VWM oligodendrocytes (activated caspase-3, bak, bax) that was most consistent in the cerebrum, the maximal locus of VWM, but was also observed in the cerebellum and central tegmental tract in the pons. The latter observation seems to confirm 1 finding of a previous study (9) . If one isolates Patient 5 and the 2 agematched controls (Controls 5 and 6), there is a clear, but statistically unverified, increase of apoptotic labeling in cerebral white matter. In contrast to the cerebrum, proapoptotic markers in the cerebellum and pons of most VWM cases were conflicting. Activated caspase-3 immunostaining revealed statistically significant elevations in the cerebellum and pons of VWM patients, while bak and bax were not significantly different from controls. In fact, the latter showed a trend toward decreased levels of immunostaining in the patients as compared to controls. This may reflect the greater tendency for these posterior fossa elements to undergo postmortem autolysis (35) . In some VWM patients apoptotic labeling was more limited or absent.
The entire apoptotic process typically lasts only a few hours from initiation to the elimination of all cellular debris (36) . Hence, in a chronic progressive disease like VWM, cells that are observed in the apoptotic phase at any given time would be relatively few. However, VWM also is marked by episodes of rapid neurological decline following events such as fever or minor head trauma. Clinically, these patients do not recover to their previous baseline following such events (1, 3) . It is reasonable, therefore, that these clinical episodes of neurological deterioration should be reflected in significant neuropathologic changes. Patients 4 and 5 had serious neurological events shortly before death; they displayed the most significant apoptotic labeling, particularly with activated caspase-3 (Table 3 ). However, patient 5 also was the youngest patient, who had the most severe phenotype (13) and a different genotype (a mutation in EIF2B2 versus ElF2B5 for Patients 1-4). Our sample size was too small to statistically verify these findings, but they do suggest that neurologic crises in this disease may correlate with an increase in oligodendrocytic apoptosis. Activated caspase-3 staining in age-matched controls was absent or markedly lower. That and the other proapoptotic labeling seen in 5 of our controls may be due to terminal hypoxia-ischemia, postmortem autolysis (16) (17) (18) (19) (37) (38) (39) (40) (41) or in Control 1 to treatment with combined chemotherapy: vincristine, bleomycin, etoposide, doxorubicin, and cyclophosphamide. The morphologic expression of both ischemic cell death and autolysis increases with time (41, 42) , and the controls had longer PMIs (15.1 Ϯ 7.5 hours) than the VWM patients (3.6 Ϯ 1.8 hours).
Future Perspectives
The fate of oligodendrocytes is the result of a balance between opposing signaling pathways for either survival or cell death (21) (22) (23) (24) (25) (26) . In VWM oligodendrocytes there appears to be a mixture of conflicting survival and apoptotic signals that varies with locale. The site dependent variability in oligodendrocytic density of VWM patients may be influenced by significant episodes of oligodendroglial loss following fever or head trauma. The deep cerebral white matter appears to be most vulnerable to these events. A normal heat-shock response, which includes the participation of eIF2B, may be necessary to prevent this loss (6, 13) . How the defect in eIF2B relates to the loss of oligodendrocytes or their proliferation or survival in VWM remains unexplained by this study. The oligodendrocytes that survive seem to upregulate antiapoptotic proteins, particularly survivin. They also may receive proliferative cues induced by the presence of newly demyelinated axons (15) , perhaps leading to more significant increases in cell number where oligodendroglia are already the most plentiful (i.e. the preserved subcortical white matter). It is noteworthy that the immunoreactive oligodendrocytes identified in our study were scattered or rarely in small clusters; large fields of immunoreactive cells, except for CAII, were never seen. This implies that internal oligodendrocytic mechanisms and/or discrete external signals, rather than highly diffusible or vascular factors, promote their death, survival, and proliferation.
This study offers no definitive evidence favoring a primary myelin defect versus a primary axonopathy, but our current results do indicate that the white matter cavitation is not solely an axonal defect. Rather, it appears to be due, at least in part, to hypomyelination or demyelination resulting from oligodendrocytic dysfunction and loss, as previously suggested (1-3, 7, 10) . Some also have invoked the participation of astrocytic dysfunction in the cavitation of VWM (8, 10) . Our study focused exclusively on cells of the oligodendrocytic series (i.e. those that are classical in morphology and CAII-positive). While CAII is an established marker of white matter oligodendrocytes that colocalizes with many others (14) , it is found in both immature and mature oligodendrocytes. In order to determine unequivocally if the proliferative or anti-apoptotic oligodendrocytes in VWM are fully mature and myelinating oligodendrocytes, we would need to provide electron microscopic evidence of labeled nuclei in cells attached to myelin sheaths. The expression of myelin proteins, such as PLP or MBP, would be the next best thing, but we were unable to accomplish this. We have had a similar experience to that of Rodriguez et al (10) : the antibody to CAII is the best for identifying cells of the oligodendrocytic series (in comparison to PLP, MBP, or CNP-ase antibodies). In view of the inability of these same investigators to demonstrate a proliferative marker in oligodendrocytes, we chose to use the antibody that labeled the most oligodendrocytes in our laboratory (i.e. to CAII) for our double immunolabeling. The enhanced efficiency of the polyclonal antibody to CAII, both a cytosolic and membrane-associated protein, is due in part to its ability to label either or both the cytoplasm and nucleus of oligodendrocytes in postmortem human white matter, such as that reported in control mice (43) and displayed by some oligodendrocytes (7, 15) . The cells double immunolabeled for Ki-67, activated caspase-3, bcl-2, survivin, and CAII in our study are also morphologically typical of oligodendrocytes, not precursor cells (14) . They may, however, be immature oligodendrocytes, but there does not appear to be a generalized immaturity of oligodendrocytes in VWM. Previous investigators have demonstrated that there are many mature myelinating oligodendrocytes in VWM by their positive staining for myelin oligodendrocyte glycoprotein (MOG), CAII, and PLP mRNA (7), as well as MBP, PLP, MOG, CAII, and CNP-ase (10) . The fact that we could not label these proliferative or anti-apoptotic oligodendrocytes for PLP cannot be taken as proof that they are not mature myelinating oligodendrocytes, because very few classical oligodendrocytes were PLP-positive, even though the staining of myelin was robust. Nor can one assume that, because they are displaying a proliferative marker, they are not mature myelinating oligodendrocytes. At least in rodents, Ludwin and Bakker have clearly demonstrated that myelinating oligodendrocytes can incorporate tritiated thymidine (44; reviewed in reference 11). Further studies are needed to determine the maturational stage of these labeled oligodendrocytes and whether oligodendroglial precursor cells participate. Given the ubiquitous underlying genetic defect in VWM, it appears likely that multiple cell lineages and developmental stages will be affected.
